Skip to main content

Advertisement

SpringerLink
Log in

Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG)

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) is a challenging condition to treat, and there is an unmet clinical need for effective therapies. Recently, polatuzumab vedotin (Pola), an anti-CD79b antibody-drug-conjugate (ADC), combined with bendamustine-rituximab (BR), has been approved for R/R DLBCL patients. However, real-world data on Pola-based regimens in R/R DLBCL patients, especially in Thailand, are limited. This study aimed to evaluate the efficacy and safety of Pola-based salvage treatment in R/R DLBCL patients in Thailand. Thirty-five patients who received Pola-based treatment were included in the study, and their data were compared to 180 matched patients who received non-Pola-based therapy. The overall response rate (ORR) in the Pola group was 62.8%, with complete remission and partial remission rates of 17.1% and 45.7%, respectively. The median progression-free survival (PFS) and overall survival (OS) were 10.6 months and 12.8 months, respectively. The study found a significantly higher ORR in Pola-based salvage treatments compared to non-Pola-based therapy (62.8% vs. 33.3%). The survival outcomes were also significantly superior in the Pola group, with longer median PFS and OS than the control group. Grades 3–4 adverse events (AEs) were mainly hematological, and they were tolerable. In conclusion, this study provides real-world evidence of the efficacy and safety of Pola-based salvage treatment in R/R DLBCL patients in Thailand. The results of this study are promising and suggest that Pola-based salvage treatment could be a viable option for R/R DLBCL patients who have limited treatment options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. National Cancer Institute (2020) Cancer stat facts: diffuse large B-cell lymphoma. https://seer.cancer.gov/statfacts/html/dlbcl.html. Accessed 9 Nov 2022

  2. Sant M, Allemani C, Tereanu C et al (2010) Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 116(19):3724–3734

    Article  CAS  PubMed  Google Scholar 

  3. Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS (2015) Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol 90(9):790–795

    Article  PubMed  Google Scholar 

  4. Intragumtornchai T, Bunworasate U, Wudhikarn K et al (2018) Non-Hodgkin lymphoma in South East Asia: an analysis of the histopathology, clinical features, and survival from Thailand. Hematol Oncol 36(1):28–36

    Article  PubMed  Google Scholar 

  5. Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235–242

    Article  CAS  PubMed  Google Scholar 

  6. Pfreundschuh M, Kuhnt E, Trumper L et al (2011) CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 12(11):1013–1022

    Article  CAS  PubMed  Google Scholar 

  7. International Non-Hodgkin’s Lymphoma Prognostic Factors P (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329(14):987–994

  8. Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769):503–511

    Article  CAS  PubMed  Google Scholar 

  9. Rosenwald A, Wright G, Chan WC et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346(25):1937–1947

    Article  PubMed  Google Scholar 

  10. Shipp MA, Ross KN, Tamayo P et al (2002) Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8(1):68–74

    Article  CAS  PubMed  Google Scholar 

  11. Sehn LH, Berry B, Chhanabhai M et al (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109(5):1857–1861

    Article  CAS  PubMed  Google Scholar 

  12. Crump M, Neelapu SS, Farooq U et al (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16):1800–1808

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Vitolo U, Trneny M, Belada D et al (2017) Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol 35(31):3529–3537

    Article  CAS  PubMed  Google Scholar 

  14. Schmitz R, Wright GW, Huang DW et al (2018) Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med 378(15):1396–1407

    Article  CAS  PubMed  Google Scholar 

  15. Gisselbrecht C, Glass B, Mounier N et al (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28(27):4184–4190

    Article  PubMed  PubMed Central  Google Scholar 

  16. Gisselbrecht C, Schmitz N, Mounier N et al (2012) Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol 30(36):4462–4469

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Nagle SJ, Woo K, Schuster SJ et al (2013) Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. Am J Hematol 88(10):890–894

    Article  CAS  PubMed  Google Scholar 

  18. Hamadani M, Hari PN, Zhang Y et al (2014) Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 20(11):1729–1736

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Crump M (2016) Management of relapsed diffuse large B-cell lymphoma. Hematol Oncol Clin North Am 30(6):1195–1213

    Article  PubMed  Google Scholar 

  20. Van Den Neste E, Schmitz N, Mounier N et al (2016) Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant 51(1):51–57

    Article  Google Scholar 

  21. Locke FL, Ghobadi A, Jacobson CA et al (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol 20(1):31–42

    Article  CAS  PubMed  Google Scholar 

  22. Abramson JS, Palomba ML, Gordon LI et al (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396(10254):839–852

    Article  PubMed  Google Scholar 

  23. Schuster SJ, Tam CS, Borchmann P et al (2021) Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 22(10):1403–1415

    Article  CAS  PubMed  Google Scholar 

  24. Westin JR, Kersten MJ, Salles G et al (2021) Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol 96(10):1295–1312

    Article  PubMed  PubMed Central  Google Scholar 

  25. The NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines®) for Diffuse large B-cell lymphoma version 5.2022 (2022) © National Comprehensive Cancer Network, Inc.

  26. Dornan D, Bennett F, Chen Y et al (2009) Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood 114(13):2721–2729

    Article  CAS  PubMed  Google Scholar 

  27. Palanca-Wessels MC, Czuczman M, Salles G et al (2015) Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol 16(6):704–715

    Article  CAS  PubMed  Google Scholar 

  28. Morschhauser F, Flinn IW, Advani R et al (2019) Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol 6(5):e254–e265

    Article  PubMed  Google Scholar 

  29. Sehn LH, Herrera AF, Flowers CR et al (2020) Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 38(2):155–165

    Article  CAS  PubMed  Google Scholar 

  30. Sehn LH, Hertzberg M, Opat S et al (2022) Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv 6(2):533–543

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Alaggio R, Amador C, Anagnostopoulos I et al (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36(7):1720–1748

  32. Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586

    Article  PubMed  Google Scholar 

  33. Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068

    Article  PubMed  PubMed Central  Google Scholar 

  34. Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed) 112(1):90–92

    Article  CAS  PubMed  Google Scholar 

  35. Wang H, Chow S-C (2014) Sample size calculation for comparing proportions. Wiley StatsRef: Statistics Reference online pp 1–16

  36. Dimou M, Papageorgiou SG, Stavroyianni N et al (2021) Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas. Hematol Oncol 39(3):336–348

    Article  CAS  PubMed  Google Scholar 

  37. Liebers N, Duell J, Fitzgerald D et al (2021) Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Adv 5(13):2707–2716

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Segman Y, Ribakovsky E, Avigdor A et al (2021) Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience. Leuk Lymphoma 62(1):118–124

    Article  CAS  PubMed  Google Scholar 

  39. Smith SD, Lopedote P, Samara Y et al (2021) Polatuzumab vedotin for relapsed/refractory aggressive B-cell lymphoma: a multicenter post-marketing analysis. Clin Lymphoma Myeloma Leuk 21(3):170–175

    Article  CAS  PubMed  Google Scholar 

  40. Northend M, Wilson W, Osborne W et al (2022) Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL. Blood Adv 6(9):2920–2926

    Article  PubMed Central  Google Scholar 

  41. Vodicka P, Benesova K, Janikova A et al (2022) Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world. Eur J Haematol 109(2):162–165

    Article  CAS  PubMed  Google Scholar 

  42. Terui Y, Rai S, Izutsu K et al (2021) A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. Cancer Sci 112(7):2845–2854

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Tilly H, Morschhauser F, Sehn LH et al (2022) Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 386(4):351–363

    Article  CAS  PubMed  Google Scholar 

  44. Song Y, Tilly H, Rai S et al (2023) Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial. Blood 141(16):1971–1981

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank the collaboration of Thai lymphoma study group (TLSG) members on behalf of the Thai Society of Hematology (TSH), who contributed to the patient care in this study.

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

    Thanawat Rattanathammethee & Lalita Norasetthada

  2. Division of Hematology and Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

    Udomsak Bunworasate, Kitsada Wudhikarn & Tanin Intragumtornchai

  3. Hematology Unit, Division of Internal Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand

    Jakrawadee Julamanee & Panarat Noiperm

  4. Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand

    Theerin Lanamtieng & Pisa Phiphitaporn

  5. Division of Hematology, Department of Medicine, Chulabhorn Hospital, Bangkok, Thailand

    Manassamon Navinpipat

  6. Division of Hematology, Department of Internal Medicine, Chiang Rai Prachanukroh Hospital, Chiang Rai, Thailand

    Piyapong Kanya

  7. Division of Hematology, Department of Medicine, Faculty of Medicine, Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand

    Dusit Jit-ueakul

  8. Division of Hematology, Department of Medicine, Khon Kaen Hospital, Khon Kaen, Thailand

    Somchai Wongkhantee & Thanongsak Suwannathen

  9. Division of Hematology, Department of Internal Medicine, Nakornping Hospital, Chiang Mai, Thailand

    Juthatip Chaloemwong

  10. Division of Hematology, Department of Medicine, Faculty of Medicine, Naresuan University, Phitsanulok, Thailand

    Peerapon Wong

  11. Division of Hematology, Department of Medicine, Faculty of Medicine, Srinakharinwirot University, Nakhon Nayok, Thailand

    Nisa Makruasi

  12. Division of Hematology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand

    Archrob Khuhapinant

  13. Division of Hematology, Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand

    Kannadit Prayongratana

  14. Division of Hematology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

    Pimjai Niparuck

  15. Division of Hematology, Department of Medicine, Thammasat University, Pathumthani, Thailand

    Nonglak Kanitsap

  16. Division of Hematology, Department of Medicine, Rajavithi Hospital, Bangkok, Thailand

    Tawatchai Suwanban

Authors
  1. Thanawat Rattanathammethee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lalita Norasetthada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Udomsak Bunworasate
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kitsada Wudhikarn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jakrawadee Julamanee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Panarat Noiperm
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Theerin Lanamtieng
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Pisa Phiphitaporn
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Manassamon Navinpipat
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Piyapong Kanya
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Dusit Jit-ueakul
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Somchai Wongkhantee
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Thanongsak Suwannathen
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Juthatip Chaloemwong
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Peerapon Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Nisa Makruasi
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Archrob Khuhapinant
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Kannadit Prayongratana
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Pimjai Niparuck
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Nonglak Kanitsap
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Tawatchai Suwanban
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Tanin Intragumtornchai
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Thanawat Rattanathammethee and Lalita Norasetthada contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Thanawat Rattanathammethee. The first draft of the manuscript was written by Thanawat Rattanathammethee. Tanin Intragumtornchai and Kitsada Wudhikarn commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Thanawat Rattanathammethee.

Ethics declarations

Ethics approval and consent to participate

The study was conducted in accordance with the International Conference on Harmonization for Good Clinical Practice guidelines and the 1964 Declaration of Helsinki. The study was approved by the ethic committees of all the participating sites (Study code: MED-2564–08034). The informed consent was exempted due to the retrospective cohort study design.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rattanathammethee, T., Norasetthada, L., Bunworasate, U. et al. Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG). Ann Hematol 102, 1887–1895 (2023). https://doi.org/10.1007/s00277-023-05273-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-023-05273-8

Keywords

Search

Navigation